OPKO Health, Inc. (NASDAQ:OPK – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $3.42.
A number of equities analysts recently issued reports on OPK shares. Piper Sandler reissued an “overweight” rating and issued a $4.00 price target (up from $3.00) on shares of OPKO Health in a research note on Friday, October 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OPKO Health in a research report on Wednesday, November 11th. Zacks Research downgraded OPKO Health from a “strong-buy” rating to a “hold” rating in a report on Friday, November 6th. UBS Group set a $4.00 target price on OPKO Health in a research report on Friday, October 16th. Finally, HC Wainwright restated a “buy” rating on shares of OPKO Health in a report on Friday, October 16th.
Get Our Latest Analysis on OPKO Health
Institutional Trading of OPKO Health
Several institutional investors have recently bought and sold shares of OPK. Virtu Financial LLC purchased a new stake in OPKO Health during the 3rd quarter valued at $245,000. Aquatic Capital Management LLC bought a new position in shares of OPKO Health during the 3rd quarter valued at $168,000. Goldman Sachs Group Inc. lifted its holdings in shares of OPKO Health by 13.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 8,005,331 shares of the biotechnology company’s stock valued at $12,889,000 after buying an additional 969,839 shares during the period. Kovack Advisors Inc. boosted its stake in shares of OPKO Health by 96.8% in the 3rd quarter. Kovack Advisors Inc. now owns 1,055,404 shares of the biotechnology company’s stock worth $1,699,000 after buying an additional 519,202 shares during the last quarter. Finally, Caxton Associates LLP purchased a new position in shares of OPKO Health in the 3rd quarter worth $452,000. 64.63% of the stock is owned by hedge funds and other institutional investors.
OPKO Health Price Performance
Shares of NASDAQ:OPK opened at $1.57 on Friday. The stock has a market cap of $1.17 billion, a PE ratio of -8.26 and a beta of 1.52. The company’s fifty day moving average is $1.61 and its 200 day moving average is $1.37. OPKO Health has a 52 week low of $0.98 and a 52 week high of $1.86. The company has a quick ratio of 4.65, a current ratio of 4.97 and a debt-to-equity ratio of 0.41.
OPKO Health (NASDAQ:OPK – Get Free Report) last issued its earnings results on Wednesday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The company had revenue of $130.83 million for the quarter, compared to the consensus estimate of $136.62 million. OPKO Health had a negative net margin of 29.51% and a negative return on equity of 10.90%. The firm’s revenue for the quarter was down 56.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.03 earnings per share. Research analysts anticipate that OPKO Health will post -0.20 earnings per share for the current year.
OPKO Health Company Profile
OPKO Health is a healthcare company with businesses in diagnostics and pharmaceuticals. Its diagnostic offerings have included BioReference Health laboratory services and the 4Kscore test, which helps assess the risk of aggressive prostate cancer. OPKO’s pharmaceutical products include Rayaldee, a prescription treatment for certain adults with chronic kidney disease and vitamin D insufficiency. The company also co-developed NGENLA, a long-acting growth hormone treatment for children with growth hormone deficiency, with Pfizer.
Featured Articles
- Five stocks we like better than OPKO Health
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
